学术搜索
科研智能体
- Research Labs
- AI 阅读
- AI 文库
- AMiner 沉思
- AMiner 亮点
学术资源
- AI2000
- 期刊/会议
- 学者库
- 学术API
- 溯源树
- 数据集
知识沉淀
- 学术空间

订阅小程序

旧版功能

aminer vip

开通会员低至0.73元/天

一次搞定AI科研

立即登录

K. Eves | AMiner学者主页 | AMiner

K. Eves

Merck & Co Inc

14Papers / 论文

30Citations / 引用

3H-Index

浏览量14

全面呈现 [K. Eves] 的学术影响力

深度挖掘高质量成果与权威引用，让优秀看得见

研究兴趣

20212022

论文（14）

专利

基金项目

按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选

1Doravirine/Islatravir (100mg/0.75mg) Once Daily Compared to Bictegravir/emtricitabine/tenofovir Alafenamide (B/F/TAF) As Initial HIV-1 Treatment: 48 Week Results from a Double-Blind Phase 3 Trial

J. K. Rockstroh,R. Paredes,P. Cahn,J. -M. Molina,S. Sokhela,F. Hinestrosa,S. Kassim, E. Valencia Ortega, D. Cunningham, J. Ghosn,J. R. Bogner,H. Gatanaga,

2023JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2023）

引用

加入学术空间

2Subgroup analysis of week 48 efficacy and safety of doravirine/islatravir (100 mg/0.75 mg) once daily as initial HIV-1 treatment in a double-blind phase 3 trial

I. Cassetti,S. Walmsley,R. Mngqibisa,J. Rockstroh,R. Paredes,C. McDonald, U. Nwoke,S. O. Klopfer, M. Karten,K. Eves,T. A. Correll,K. Squires,

2023HIV MEDICINE（2023）

引用

加入学术空间

3Switch to Fixed-Dose Doravirine (100 Mg) with Islatravir (0.75 Mg) Once Daily in Adults with HIV-1 Virologically Suppressed on Antiretroviral Therapy: Week 96 Results of a Randomized, Open-Label, Phase 3 Trial

J. -M. Molina,G. Rizzardini,S. Kassim,A. Afani Saud,A. Calmy,S. Oka,F. Hinestrosa, P. Kumar,P. Tebas,S. Walmsley,A. Grandhi,S. Klopfer,

2023HIV MEDICINE（2023）

引用

加入学术空间

4Efficacy and Safety by Subgroup at Week 48 after Switch to Doravirine/islatravir (100 Mg/0.75 Mg) Once Daily in Two Phase 3 Trials

J. -M. Molina,A. M. Mills,A. Afani Saud,J. R. Bogner,A. Calmy,A. Carr,D. P. Hagins,F. Hinestrosa,P. N. Kumar,S. Oka,C. Orrell,O. Osiyemi,

2023HIV MEDICINE（2023）

引用

加入学术空间

5Total lymphocyte and CD4+T-cell count changes in participants receiving islatravir (0.25, 0.75 and 2.25 mg QD) and doravirine plus /- lamivudine: post-hoc analysis from a phase 2b dose- ranging study (P011)

T. Correll,J. Molina,S. Klopfer,A. Grandhi,R. Lahoulou,Y-P Zhou,K. Eves,K. Squires

2022JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2022）

引用

加入学术空间

6Islatravir safety analysis through week 96 from a Phase 2 trial in treatment naive adults with HIV-1 infection

D. Cunningham,J-M Molina,Y. Yazdanpanah,A. A. Saud,C. C. Anania,S. O. Klopfer,A. Grandhi,K. Eves,D. Hepler,C. Hwang,R. Lahoulou,T. A. Correll

2021JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2021）引用：3

引用

加入学术空间

7Efficacy and safety of islatravir in combination with doravirine through 144 weeks for treatment-naive adults with HIV-1 infection in a phase 2b trial

J. -M. Molina,Y. Yazdanpanah,A. Afani Saud,C. Bettacchi,C. Chahin Anania,S. Olsen Klopfer,A. Grandhi,K. Eves,D. Hepler,R. Lahoulou,T. Correll

2021HIV MEDICINE（2021）

引用

加入学术空间

8Renal safety through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1

F. Post,C. McMullan, G. DiPerri,J. Molina,S. Klopfer,A. Grandhi,K. Eves,D. Hepler,C. Hwang,T. Correll

2020JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2020）

引用

加入学术空间

9Islatravir Safety Analysis Through Week 48 from a Phase 2 Trial in Treatment Naive Adults with HIV-1 Infection

E. DeJesus,J. -M. Molina,Y. Yazdanpanah,A. Afani Saud,C. Bettacchi,C. Chahin Anania,S. Klopfer,A. Grandhi,K. Eves,M. Robertson,P. Sklar,C. Hwang,

2020JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2020）引用：2

引用

加入学术空间

10Islatravir in Combination with Doravirine Maintains HIV-1 Viral Suppression Through 96 Weeks

J. Molina,Y. Yazdanpanah,A. Afani Saud,C. Bettacchi,C. Chahin Anania,E. DeJesus,S. Klopfer,A. Grandhi,K. Eves,D. Hepler,M. Robertson,C. Hwang,

2020JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2020）引用：10

引用

加入学术空间

11Analysis of protocol defined virologic failure through week 48 from a phase 2 trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1 infection

C. Orkin,J. -M. Molina,Y. Yazdanpanah, C. Chahlin Anania,E. DeJesus,J. Eron,S. Klopfer,A. Grandhi,K. Eves, D. Rudd,M. Robertson,P. Sklar,

2020JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2020）引用：1

引用

加入学术空间

12Analysis of protocol-defined virologic failure through 96 weeks from a phase II trial (P011) of islatravir and doravirine in treatment-naive adults with HIV-1

C. Orkin,J. Molina,Y. Yazdanpanah,C. Chahin Anania,E. DeJesus,J. Eron,S. Klopfer,A. Grandhi,J. Xu,K. Eves,D. Hepler,M. Robertson,

2020JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2020）引用：5

引用

加入学术空间

13MK-8591 at doses of 0.25 to 2.25 mg QD, in combination with doravirine establishes and maintains viral suppression through 48 weeks in treatment-naive adults with HIV-1 infection

J. -M. Molina,Y. Yazdanpanah,A. Afani Saud,C. Bettacchi,C. Chahin Anania,E. DeJesus,S. O. Klopfer,K. Eves,A. Grandhi,M. N. Robertson,C. Hwang,G. Hanna,

2019JOURNAL OF THE INTERNATIONAL AIDS SOCIETY（2019）引用：8

引用

加入学术空间

14Islatravir efficacy and safety for selected demographic and baseline subgroups from a Phase 2 trial in treatment naive adults with HIV-1 infection

J-M Molina,Y. Yazdanpanah,A. Afani Saud,C. Bettacchi,C. Chahin Anania,E. DeJesus,S. Klopfer,A. Grandhi,K. Eves,M. Robertson,T. Correll,C. Hwang,

2019HIV MEDICINE（2019）引用：1

引用

加入学术空间

作者统计

合作学者

合作机构

D-Core

合作者
学生
导师

Anjana Grandhi合作论文数Merck & Co Inc12

T. Correll

T. Correll合作论文数9

J M Molina

J M Molina合作论文数8

A. Afani Saud

A. Afani Saud合作论文数8

Klopfer Stephanie O

Klopfer Stephanie O合作论文数8

Ck Hwang合作论文数8

Yazdan Yazdanpanah合作论文数Université Paris Cité8

C. Chahin Anania

C. Chahin Anania合作论文数7

G. Hanna

G. Hanna合作论文数6

S. O. Klopfer

S. O. Klopfer合作论文数6

Edwin Dejesus

Edwin Dejesus合作论文数6

Michael Robertson合作论文数6

Deborah Hepler

Deborah Hepler合作论文数5

C. Bettacchi

C. Bettacchi合作论文数5

J. Molina

J. Molina合作论文数4

T. A. Correll

T. A. Correll合作论文数4

P Sklar

P Sklar合作论文数4

R. Lahoulou

R. Lahoulou合作论文数3

M. C. Fox

M. C. Fox合作论文数3

Roger Paredes合作论文数3

K Squires

K Squires合作论文数3

Sharon Walmsley

Sharon Walmsley合作论文数3

Hinestrosa Federico

Hinestrosa Federico合作论文数3

S. Kassim

S. Kassim合作论文数2

J. Rockstroh

J. Rockstroh合作论文数2

Joseph J. Eron合作论文数Division of Infectious Diseases, Department of Medicine, School of Medical, University of North Carolina at Chapel Hill;Center for AIDS Research, University of North Carolina at Chapel Hill2

Pablo Tebas合作论文数Department of Medicine, Perelman School of Medicine, University of Pennsylvania2

Shiro Oka (岡志郎)合作论文数Department of Gastroenterology, Graduate School of Biomedical and Health Sciences, Hiroshima University;Department of Gastroenterology and Metabolism, Hiroshima University2

Johannes Bogner合作论文数LMU University Hospital Munich2

Alexandra Calmy合作论文数Department of Medicine, Faculty of Medicine, University of Geneva2

Chloe Orkin合作论文数Blizard Institute, Faculty of Medicine and Dentistry, Queen Mary University of London;Centre for Immunobiology, Queen Mary University of London;Barts Health NHS Trust2

Giuliano Rizzardini合作论文数Department of Infectious Diseases, S. Anna Hospital2

A. M. Mills

A. M. Mills合作论文数1

D. P. Hagins

D. P. Hagins合作论文数1

Yun-Ping Zhou

Yun-Ping Zhou合作论文数1

C. McMullan

C. McMullan合作论文数1

S. Sokhela

S. Sokhela合作论文数1

I. Cassetti

I. Cassetti合作论文数1

C. McDonald

C. McDonald合作论文数1

J. Xu

J. Xu合作论文数1

Jean-Michel Molina合作论文数Institut Pasteur1

Osiyemi Olayemi

Osiyemi Olayemi合作论文数1

Carr A

Carr A合作论文数1

Mngqibisa Rosie

Mngqibisa Rosie合作论文数1

Ramgopal Moti

Ramgopal Moti合作论文数1

Asante-Appiah Ernest

Asante-Appiah Ernest合作论文数1

Gatanaga H

Gatanaga H合作论文数1

Jacques Reynes合作论文数Hôpital Gui de Chauliac, Centre Hospitalier Universitaire de Montpellier;Faculté de Médecine de Montpellier;Département des Maladies Infectieuses et Tropicales, CHU de Montpellier1

Princy N. Kumar合作论文数School of Medicine, Georgetown University1

相似学者

Klopfer Stephanie O

Klopfer Stephanie O

Yazdan Yazdanpanah

C. Chahin Anania

C. Chahin Anania

数据免责声明

页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果，我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问，可以通过电子邮件方式联系我们：report@aminer.cn